Yahoo Finance reports:
Novavax is the latest biotech company to announce that it is entering its vaccine in clinical trials. It’s recombinant technology, already tested in a late-stage flu vaccine trial, focuses on using DNA from the virus to create a vaccine.
The Phase 1 clinical trial in Australia is the first in the Southern Hemisphere, and is focusing on 130 participants. Pre-clinical data showed a lower dose of the vaccine was effective, which lays a foundation for potentially greater volumes of the vaccine to be produced.
Dr. Gregory Glenn, president of Novavax’s research and development, told Yahoo Finance Tuesday that the company is aiming to produce 100 million doses by the end of the year, and 1 billion by 2021. Trial results are expected as early as July, with a vaccine ready for emergency use by the fall.